ティーセルヌーヴォー㈱
Tokyo, JP · 1 known investors
Find your way into ティーセルヌーヴォー㈱
T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.
Founders & leadership
HS
Hiroshi ShikuFounder
KM
Kosuke MatsunagainPresident & CEO
Investors · 1
Frequently asked questions
- What does ティーセルヌーヴォー㈱ do?
- T Cell Nouveau develops Hybrid CAR-T cell therapies designed to treat solid tumors by enhancing immune system activation in suppressive tumor microenvironments. The clinical-stage biopharmaceutical company targets cancer patients and originated from research conducted at Mie University's Personalized Cancer Immunotherapy department.
- Who founded ティーセルヌーヴォー㈱?
- ティーセルヌーヴォー㈱ was founded by Hiroshi Shiku.
- Who are ティーセルヌーヴォー㈱'s investors?
- ティーセルヌーヴォー㈱'s investors include DBJ Capital.
- Where is ティーセルヌーヴォー㈱ headquartered?
- ティーセルヌーヴォー㈱ is headquartered in Tokyo, JP.